JP6774951B2 - 癌処置をガイドするためのコンテクストに依存する診断試験 - Google Patents

癌処置をガイドするためのコンテクストに依存する診断試験 Download PDF

Info

Publication number
JP6774951B2
JP6774951B2 JP2017536828A JP2017536828A JP6774951B2 JP 6774951 B2 JP6774951 B2 JP 6774951B2 JP 2017536828 A JP2017536828 A JP 2017536828A JP 2017536828 A JP2017536828 A JP 2017536828A JP 6774951 B2 JP6774951 B2 JP 6774951B2
Authority
JP
Japan
Prior art keywords
cancer
patient
cell
patients
response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017536828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018503092A5 (https=
JP2018503092A (ja
Inventor
エリシャ ジェイ． デットマン，
エリシャ ジェイ． デットマン，
マイケル エイチ． カーダン，
マイケル エイチ． カーダン，
Original Assignee
ユートロピクス ファーマシューティカルズ， インコーポレイテッド
ユートロピクス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユートロピクス ファーマシューティカルズ， インコーポレイテッド, ユートロピクス ファーマシューティカルズ， インコーポレイテッド filed Critical ユートロピクス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2018503092A publication Critical patent/JP2018503092A/ja
Publication of JP2018503092A5 publication Critical patent/JP2018503092A5/ja
Application granted granted Critical
Publication of JP6774951B2 publication Critical patent/JP6774951B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Data Mining & Analysis (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Evolutionary Computation (AREA)
  • Bioethics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
JP2017536828A 2015-01-12 2016-01-12 癌処置をガイドするためのコンテクストに依存する診断試験 Expired - Fee Related JP6774951B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562102499P 2015-01-12 2015-01-12
US62/102,499 2015-01-12
PCT/US2016/013003 WO2016115105A1 (en) 2015-01-12 2016-01-12 Context dependent diagnostics test for guiding cancer treatment

Publications (3)

Publication Number Publication Date
JP2018503092A JP2018503092A (ja) 2018-02-01
JP2018503092A5 JP2018503092A5 (https=) 2019-01-24
JP6774951B2 true JP6774951B2 (ja) 2020-11-04

Family

ID=56406281

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017536828A Expired - Fee Related JP6774951B2 (ja) 2015-01-12 2016-01-12 癌処置をガイドするためのコンテクストに依存する診断試験

Country Status (9)

Country Link
US (2) US10793915B2 (https=)
EP (1) EP3245301B1 (https=)
JP (1) JP6774951B2 (https=)
KR (1) KR20170126867A (https=)
CN (1) CN107406881B (https=)
AU (1) AU2016206882B2 (https=)
CA (1) CA2974240A1 (https=)
HK (1) HK1247250A1 (https=)
WO (1) WO2016115105A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9901574B2 (en) 2015-04-20 2018-02-27 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
ES2739749T3 (es) 2015-05-18 2020-02-03 Tolero Pharmaceuticals Inc Profármacos de alvocidib que tienen biodisponibilidad aumentada
MX2018001289A (es) 2015-08-03 2018-04-30 Tolero Pharmaceuticals Inc Terapias de combinacion para el tratamiento del cancer.
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
KR20190099260A (ko) 2016-12-19 2019-08-26 톨레로 파마수티컬스, 인크. 프로파일링 펩티드 및 감도 프로파일링을 위한 방법
EP3385715A1 (en) 2017-04-04 2018-10-10 Medizinische Hochschule Hannover Analytical process for predicting the therapeutic effect of bh3 mimetics
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
CN108070562A (zh) * 2018-02-03 2018-05-25 金华市中心医院 一种“双打击”弥漫大b细胞淋巴瘤细胞系制备方法
PT110722B (pt) * 2018-05-03 2021-08-17 Instituto De Patologia E Imunologia Molecular Da Univ Do Porto Ipatimup Uso de anticorpos para o antigénio thomsen-friedenreich num método e estojo para avaliação de instabilidade de microsatelites
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
US20230187075A1 (en) * 2021-12-14 2023-06-15 Shuhua Zheng Method and system for artificial intelligence based risk stratification for glioma

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622852A (en) 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
GB9422836D0 (en) * 1994-11-11 1995-01-04 Wainscoat James Monitoring malignant disease
US5955593A (en) 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
WO1998009643A1 (en) 1996-09-09 1998-03-12 Washington University Modulation of apoptosis by serine phosphorylation of blc-xl/blc-2 associated cell death regulator
US5856445A (en) 1996-10-18 1999-01-05 Washington University Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
US5981201A (en) 1997-01-08 1999-11-09 Beth Israel Deaconess Medical Center Methods of detection and treatment of breast cancer
GB9704444D0 (en) 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
WO1999014321A1 (en) 1997-09-17 1999-03-25 The Walter And Eliza Hall Institute Of Medical Research Novel therapeutic molecules
AU9402898A (en) 1997-09-26 1999-04-23 Washington University Cell death agonists
US6165732A (en) 1997-10-14 2000-12-26 Washington University Method for identifying apoptosis modulating compounds
US7026456B1 (en) 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
AU762756B2 (en) 1998-05-18 2003-07-03 Apoptosis Technology, Inc. Compounds, screening methods, and uses involving anti-apoptotic genes and gene products
US6326354B1 (en) 1998-08-19 2001-12-04 Washington University Modulation of apoptosis with bid
AU5233799A (en) 1998-08-19 2000-03-14 Washington University Modulation of apoptosis with bid
WO2002005835A2 (en) 2000-07-17 2002-01-24 Washington University Modulation of apoptosis
US20020177692A1 (en) 2001-04-16 2002-11-28 Myriad Genetics, Incorporated BCL-XL-interacting protein and use thereof
US20030073661A1 (en) 2001-09-24 2003-04-17 Shigemi Matsuyama Method of modulating or examining Ku70 levels in cells
AU2002364364A1 (en) 2001-12-31 2003-07-24 Dana-Farber Cancer Institute, Inc. Method of treating apoptosis and compositions thereof
WO2004022580A2 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
RU2345137C2 (ru) 2002-12-26 2009-01-27 Закрытое акционерное общество "ЕВРОГЕН" Флуоресцирующие белки из веслоногих ракообразных и способы их применения
CA2521077A1 (en) 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Erbb surface receptor complexes as biomarkers
FR2855650B1 (fr) 2003-05-30 2006-03-03 Soitec Silicon On Insulator Substrats pour systemes contraints et procede de croissance cristalline sur un tel substrat
CN1302004C (zh) 2003-08-22 2007-02-28 浙江海正药业股份有限公司 一种阿糖胞苷的制备方法
EP1997828B1 (en) 2003-11-05 2017-10-04 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides from BCL-2 and uses thereof
WO2005079434A2 (en) 2004-02-17 2005-09-01 The University Of North Carolina At Chapel Hill Modulation of epidermal growth factor heterodimer activity
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP2008106A2 (en) 2006-03-31 2008-12-31 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
WO2008021484A2 (en) 2006-08-16 2008-02-21 Eutropics Pharmaceuticals Assay system to identify therapeutic agents
EP2952522B1 (en) 2007-01-31 2019-10-30 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
US20090030005A1 (en) 2007-07-19 2009-01-29 Amgen Inc. Combinations for the treatment of cancer
EP2649997B1 (en) 2007-12-10 2019-01-23 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome
US8168755B2 (en) 2008-05-07 2012-05-01 Eutropics Pharmaceuticals, Inc. Antibodies specific to heterodimers of Bcl-2 family and uses thereof
US20100015058A1 (en) 2008-06-25 2010-01-21 Stanford University Radiolabeled bbn-rgd heterodimers for cancer targeting
US9492449B2 (en) * 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
MX2011008488A (es) 2009-02-11 2011-10-24 Abbott Lab Metodos y composiciones para identificar, clasificar y monitorear individuos que tienen tumores y canceres resistentes al inhibidor de la familia de bcl-2.
JP5718319B2 (ja) 2009-05-14 2015-05-13 ネステク ソシエテ アノニム Ｈｅｒ２標的化療法に対する乳癌細胞の感受性を決定するためのバイオマーカー
WO2011088137A2 (en) 2010-01-12 2011-07-21 H. Lee Moffitt Cancer Center & Research Institute Bad pathway gene signature
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
US9051305B2 (en) 2011-03-08 2015-06-09 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
US9012215B2 (en) * 2011-09-22 2015-04-21 The Johns Hopkins University Methods for identifying leukemia stem cells and distinguishing them from normal hematopietic stem cells in patients with acute myeloid leukemia: uses in diagnosis, treatment, and research
WO2013138702A2 (en) 2012-03-15 2013-09-19 Bristol-Myers Squibb Company Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
KR102062416B1 (ko) 2012-05-10 2020-01-03 유트로픽스 파마슈티컬스, 인크. 실용 가능한 암 진단 대체 법
HK1213046A1 (zh) 2012-09-19 2016-06-24 Dana-Farber Cancer Institute, Inc. 動態bh3分析
EP2922544B1 (en) * 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
CA2922503C (en) 2013-09-19 2021-10-26 Dana-Farber Cancer Institute, Inc. Methods of bh3 profiling
WO2015066305A1 (en) * 2013-10-30 2015-05-07 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
AU2016253957C1 (en) 2015-04-27 2021-04-01 Dana-Farber Cancer Institute, Inc. High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells

Also Published As

Publication number Publication date
KR20170126867A (ko) 2017-11-20
US10793915B2 (en) 2020-10-06
CN107406881A (zh) 2017-11-28
WO2016115105A1 (en) 2016-07-21
AU2016206882B2 (en) 2022-03-10
US20180340229A1 (en) 2018-11-29
US20200392585A1 (en) 2020-12-17
EP3245301B1 (en) 2020-11-11
EP3245301A1 (en) 2017-11-22
CA2974240A1 (en) 2016-07-21
EP3245301A4 (en) 2018-11-21
AU2016206882A1 (en) 2017-07-27
JP2018503092A (ja) 2018-02-01
CN107406881B (zh) 2021-05-25
HK1247250A1 (zh) 2018-09-21

Similar Documents

Publication Publication Date Title
JP6774951B2 (ja) 癌処置をガイドするためのコンテクストに依存する診断試験
US10624880B2 (en) Predicting response to alvocidib by mitochondrial profiling
US11519015B2 (en) Methods for determining chemosensitivity and chemotoxicity
US20190257816A1 (en) Differential bh3 mitochondrial profiling
JP2018013498A (ja) 癌に対する補助的機能診断テスト
HK40022688B (en) Predicting response to alvocidib by mitochondrial profiling
HK40022688A (en) Predicting response to alvocidib by mitochondrial profiling
HK1228469A1 (en) Methods for determining chemosensitivity and chemotoxicity
HK1228469B (en) Methods for determining chemosensitivity and chemotoxicity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200902

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200918

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201005

R150 Certificate of patent or registration of utility model

Ref document number: 6774951

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees